Opioid withdrawal syndrome is the profound neurochemical brain injury which drives the compulsive dynamic of repeated relapse, overdose, and death among those struggling to achieve sustained recovery.  Opioid exposure terminates the brain’s organic ability to produce the body’s baseline survival chemicals – dopamine and serotonin. Decades of open label clinical studies have produced an abundance of observational data which suggest that a psychoactive alkaloid called ibogaine resolves opioid withdrawal syndrome within 48 to 72 hours when properly administered in a clinically controlled medical setting.  It has the singular unique ability to clear and reset the brain’s opioid receptors while also restoring the brain’s organic dopamine and serotonin production to pre-opioid exposure levels – a process which doesn’t otherwise begin to occur until a person has been completely abstinent for 18 months.

Ibogaine’s effects extend to individuals suffering from methamphetamine, cocaine, and alcohol dependency. Ibogaine fully resolves physiological substance dependence within80% of individuals with a single treatment and 97% of individuals with a second supportive dose.

On January 5, 2024, the internationally esteemed medical research journal “Nature Medicine” published the phenomenal results of a groundbreaking study of a cohort of U.S. SpecialForces veterans who traveled to Mexico to receive ibogaine treatment for traumatic brain injuries and post-traumatic stress disorder.  A single treatment fully resolved all their symptomatology which also included treatment resistant depression and anxiety.  Diagnostic imaging studies confirmed that ibogaine has broad-based regenerative effects on the human brain which include the global restoration of white matter, the enlargement of brain structures responsible for emotional regulation and executive functioning, and a reversal of physiologic brain age.  In the words of the study’s chief investigator, Dr. Nolan Williams, the data demonstrate that “Ibogaine is the most sophisticated drug on the planet.”  Ibogaine is a legal medication in Mexico, Brazil, New Zealand and South Africa.

Texas can become the epicenter of developmental gravity for all of ibogaine’s advanced therapeutic applications by committing $50,000,000 in state funds to create a public private partnership which would develop and execute FDA-approved clinical trials with ibogaine in conjunction with research universities such as the University of Texas, Texas Tech, andBaylor University. Within this model, Texas will preserve its commercialization interests in any patentable intellectual property which will be produced by this endeavor.  By doing so, Texas will pioneer the creation of a revolutionary new field of biomedical research and development, bringing curative relief to millions of individuals who lack access to effective treatment for intractable, debilitating conditions.